FDA Approves First Gene Therapy for Genetic Hearing Loss and Other Biotech Updates

Regeneron Pharmaceuticals Gene Therapy Receives FDA Approval for Rare Genetic Hearing Loss

The U.S. Food and Drug Administration (FDA) has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy, for the treatment of severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene, according to a press release from the FDA. This marks the first gene therapy product approved under the Commissioner’s National Priority Voucher (CNPV) pilot program and the sixth approval under the initiative, which aims to accelerate therapies for rare diseases with unmet medical needs.

Genetic mutations cause about half of congenital hearing loss, with OTOF variants accounting for 2% to 8% of inherited, non-syndromic cases. Patients with two nonworking copies do not produce otoferlin, disrupting sound signal transmission. Prior to Otarmeni’s approval, no disease modifying treatments existed for OTOF-related deafness.

Clinical Trial Breakdown: Efficacy and Safety Profile

Approval was based on a single, ongoing, multi-center, single-arm clinical trial in 24 pediatric patients aged 10 months to 16 years. Out of 20 patients assessed for effectiveness, 80% showed enhanced hearing, an outcome not typically observed in the disease’s progression without treatment. Administered as a single dose per ear through surgery into the cochlea using a syringe and catheter, the therapy provides a functional OTOF gene copy to inner hair cells, restoring otoferlin production and auditory signaling.

Common side effects included middle ear infection, nausea, dizziness, and procedural pain. The FDA emphasized the need for providers to monitor for surgical complications, cautioning that the therapy is not recommended for patients with anatomy that prevents safe access to the inner ear. The therapy’s safety and effectiveness were based on results from the trial, with confirmatory evidence including mechanistic nonclinical data and sustained otoferlin protein expression post-Otarmeni administration.

“Today’s approval is a significant milestone in the treatment of genetic hearing loss,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Through the national priority voucher pilot program, the agency is accelerating therapies for rare diseases with unmet medical needs while proving we can successfully review even the most complex submissions—such as novel dual vector gene therapies and combination products requiring coordination across multiple offices and centers—in significantly shortened timeframes.”

Biological Mechanism and Manufacturing Innovation

Otarmeni employs a dual AAV serotype 1 (AAV1) vector gene therapy. It is a one time biologic-device combination product.

Funding and Regulatory Context

The application received orphan drug, rare pediatric disease, fast track, and regenerative medicine advanced therapy (RMAT) designations. The FDA granted accelerated approval of Otarmeni to Regeneron Pharmaceuticals, Inc. Ongoing approval could depend on evaluating the persistence of hearing improvement and confirming the therapy’s effects on speech development and quality of life indicators.

Directory Bridge: Connecting Patients and Providers

For patients with OTOF-related hearing loss, the approval of Otarmeni opens new avenues for treatment.

Future Implications and Research Directions

The approval of Otarmeni highlights the role of gene therapy in treating rare genetic conditions.

With the FDA planning a public meeting on June 4, 2026, to gather input on the CNPV pilot program’s eligibility criteria, voucher selection process, sponsor responsibilities, pre-submission requirements, FDA review procedures, and the program’s role, stakeholders will be closely monitoring how regulatory structures develop to foster innovation in rare disease treatments.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.